Guideline Implementation, Drug Sequencing, and Quality of Care in Heart Failure: Design and Rationale of TITRATE-HF

Figures

• 

  Figure 1. Overview of proposed sequencing strategies. ACE‐I, angiotensin‐converting enzyme inhibitor; AF, atrial fibrillation; ARB, angiotensin II receptor blocker; ARNI, angiotensin receptor–neprilysin inhibitor; BB, beta‐blocker; BP, blood pressure; CKD, chronic kidney disease; HK, hyperkalaemia; HR, heart rate; MRA, mineralocorticoid receptor antagonist; SGLT2i, sodium–glucose co‐transporter 2 inhibitor.

• 

  Figure 2. Data collection structure with time windows. ACE‐I, angiotensin‐converting enzyme inhibitor; ARB, angiotensin II receptor blocker; ARNI, angiotensin receptor–neprilysin inhibitor; ECG, electrocardiogram; HF, heart failure; MRA, mineralocorticoid receptor antagonist; NYHA, New York Heart Association; SGLT2i, sodium–glucose co‐transporter 2 inhibitor. 1If unavailable, max 6 months old. 2If unavailable, most recent. 3If unavailable, max 3 months old. 4Target dose only applicable for the four drug classes.